Moderna delivered one of its biggest single-day moves of the year on Friday, Oct 9. The stock closed 14.2% higher at $225, up from Thursday's $197 finish. It opened at $199, slipped as low as $197.17, then climbed steadily to end at the session high. The Nasdaq gained just 0.64% the same day. Moderna's move was about 22 times the index gain. The close set a new 52-week high, which the Economic Times called the stock's strongest level since 2021.
The push came from Washington, not the earnings calendar. On Friday morning the New York Times described a planned NIH-backed national drive to accelerate personalized cancer vaccines. It would be built along the lines of the public-private COVID collaboration. The National Cancer Institute's Dr. Anthony Letai is calling for a country-wide effort. The partnership would bring together the NIH and its charitable arm, the Foundation for NIH. University researchers, drugmakers, patient groups and charities would join too. Foundation for NIH clinical officer Stacey Adam said the program could start in December. That gives the sector a dated, funded catalyst rather than a bare headline.
A second force was mechanical. Before Friday's opening bell, Moderna took its place back in the Nasdaq-100, replacing Warner Bros. Discovery. Nasdaq revealed the change on Oct 1. More than 200 index-tracking funds hold upwards of $800 billion in assets. All of them now have to carry the stock.
Why it matters
Moderna remains the most recognizable dedicated mRNA company. Its headline asset is intismeran autogene, the tailor-made cancer vaccine it is building with Merck. The pair reported on Aug 19 that the combination with Merck's Keytruda had succeeded in the final-stage INTerpath-001 study. It cleared its main goal — the first individualized neoantigen treatment ever to do so. Complete results reach the ESMO congress in Madrid on Oct 24. A federal-backed national program leaves that trial's outcome untouched. But it stretches the demand story from one company's pipeline across a whole drug class. Friday's rally reflected that broader bid. Novavax added roughly 16% to end near $13, and Vaxcyte gained about 10%. BioNTech rose around 5%; Merck and Pfizer each added close to 2%.
What to watch
- Oct 24 — complete INTerpath-001 results at the ESMO congress in Madrid
- December — the planned start of the NIH-backed program, per the Foundation for NIH
- Funding scale, trial design and partner details as the program takes shape
MarketRadar take
Friday paired two different buyers. Policy money reacted to a dated national program; index money was forced to own the stock after the Nasdaq-100 reentry. That is flow-positive for MRNA into the Oct 24 ESMO readout, the next real scientific checkpoint. The caution flag is price. At $225 — about ten times the November low and far above where analysts sat — the stock is priced for confirmation, not surprise.
